OncLive - In our exclusive interview, Toni K. Choueiri, MD, provides perspective on the FDA approval of nivolumab and cabozantinib in advanced renal cell...
Articles from: OncLive
Durvalumab, Osimertinib Envelop Adjuvant and Neoadjuvant NSCLC Treatment
posted 2 days
Mashup Score: 2
OncLive - The sustained overall survival benefit with durvalumab and significant disease-free survival benefit benefit with osimertinib in the adjuvant setting represent major advances in the...
-
Durvalumab, Osimertinib Envelop Adjuvant and Neoadjuvant NSCLC Treatment @ZPiotrowskaMD @MassGeneralNews #lcsm https://t.co/4w2MWgKwzG
Immunotherapy Finds a Role in Frontline Small Cell Lung Cancer and Mesothelioma
posted 2 days
Mashup Score: 2
OncLive - Checkpoint inhibitors have failed to improve progression-free survival and overall survival as second-line therapy and maintenance therapy in small cell lung cancer, but this...
-
Checkpoint inhibitors have failed to improve PFS and overall survival as second-line therapy and maintenance therapy in SCLC, but this class of agents continue to show encouraging activity worthy of a paradigm shift up front. @ColumbiaMed @gotoPER #lcsm https://t.co/d8m7SMfG1f
Novartis Signs In-Licensing Agreement With BeiGene to Expand Tislelizumab Trials Globally
posted 17 hours
Mashup Score: 1
OncLive - January 26, 2021 – Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside...
-
Novartis Signs In-Licensing Agreement With BeiGene to Expand Tislelizumab Trials Globally https://t.co/azPTfw5HHQ
Immunotherapy Could Restore the Value of Neoadjuvant Therapy in Lung Cancer
posted 15 hours
Mashup Score: 1
OncLive - David Spigel, MD, discusses ongoing research with immunotherapy in early-stage lung...
-
.@dave6408, of @SarahCannonDocs, discusses ongoing research with immunotherapy in early-stage lung cancer #lcsm https://t.co/aH3FJK7Qg1 https://t.co/aH3FJK7Qg1
Lung-Sparing Nodule Resection Gains Traction in Lung Cancer, But Needs Multidisciplinary Considerations
posted 7 hours
Mashup Score: 1
OncLive - Henning Gaissert, MD, discusses the importance of tailoring surgical resection strategies to individual patients with lung...
-
Although lung-sparing lung nodule resection in the form of lesser resection is available to some patients with lung cancer, it is critical to tailor surgical interventions based on pathologic assessment results. @MassGeneralNews #lcsm https://t.co/xbeETMila7
Avelumab Approved in Europe for Frontline Maintenance in Metastatic Urothelial Carcinoma
posted 2 days
Mashup Score: 1
OncLive - January 25, 2021 – The European Commission has approved avelumab for use as a frontline maintenance option in the treatment of adult patients with...
-
Avelumab Approved in Europe for Frontline Maintenance in Metastatic Urothelial Carcinoma @tompowles1 @QMBCI https://t.co/yREWBxICFP
OncLive - January 25, 2021 – The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal...
-
Toripalimab Granted @US_FDA Fast Track Status for Mucosal Melanoma #melsm https://t.co/8sH2UyCVSi
Frontline Pembrolizumab Approved in Europe for Metastatic MSI-H/dMMR CRC
posted 20 hours
Mashup Score: 1
OncLive - January 26, 2021 – The European Commission has approved single-agent pembrolizumab for use in the frontline treatment of patients with metastatic microsatellite instability–high or...
-
Frontline Pembrolizumab Approved in Europe for Metastatic MSI-H/dMMR CRC #crcsm https://t.co/4bpVp3Mjor
Lung-Sparing Nodule Resection Gains Traction in Lung Cancer, But Needs Multidisciplinary Considerations
posted 2 days
Mashup Score: 1
OncLive - Henning Gaissert, MD, discusses the importance of tailoring surgical resection strategies to individual patients with lung...
-
Although lung-sparing lung nodule resection in the form of lesser resection is available to some patients with lung cancer, it is critical to tailor surgical interventions based on pathologic assessment results. @MassGeneralNews #lcsm https://t.co/QiY6tTJqa7
LISTEN: In our exclusive interview, @DrChoueiri provides perspective on the FDA approval of nivolumab and cabozantinib in advanced renal cell carcinoma #kcsm https://t.co/2u4EbaxJkK https://t.co/2u4EbaxJkK